AT-752 targets multiple sites and activities on the Dengue virus replication enzyme NS5.
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
20
11
2022
revised:
26
02
2023
accepted:
27
02
2023
medline:
11
4
2023
pubmed:
12
3
2023
entrez:
11
3
2023
Statut:
ppublish
Résumé
AT-752 is a guanosine analogue prodrug active against dengue virus (DENV). In infected cells, it is metabolized into 2'-methyl-2'-fluoro guanosine 5'-triphosphate (AT-9010) which inhibits RNA synthesis in acting as a RNA chain terminator. Here we show that AT-9010 has several modes of action on DENV full-length NS5. AT-9010 does not inhibit the primer pppApG synthesis step significantly. However, AT-9010 targets two NS5-associated enzyme activities, the RNA 2'-O-MTase and the RNA-dependent RNA polymerase (RdRp) at its RNA elongation step. Crystal structure and RNA methyltransferase (MTase) activities of the DENV 2 MTase domain in complex with AT-9010 at 1.97 Å resolution shows the latter bound to the GTP/RNA-cap binding site, accounting for the observed inhibition of 2'-O but not N7-methylation activity. AT-9010 is discriminated ∼10 to 14-fold against GTP at the NS5 active site of all four DENV1-4 NS5 RdRps, arguing for significant inhibition through viral RNA synthesis termination. In Huh-7 cells, DENV1-4 are equally sensitive to AT-281, the free base of AT-752 (EC
Identifiants
pubmed: 36905944
pii: S0166-3542(23)00052-9
doi: 10.1016/j.antiviral.2023.105574
pii:
doi:
Substances chimiques
Guanosine
12133JR80S
Guanosine Triphosphate
86-01-1
RNA, Viral
0
Viral Nonstructural Proteins
0
AT-752
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105574Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest S.G., K.L., A.M. and J.P.S. are employees of ATEA Pharmaceuticals, Inc. The other authors declare no competing interests.